InvestorsHub Logo
Followers 737
Posts 75960
Boards Moderated 0
Alias Born 01/01/2012

Re: surfgreen post# 67066

Monday, 03/06/2017 6:05:08 PM

Monday, March 06, 2017 6:05:08 PM

Post# of 203913
Who exactly is conducting the research for OWCP on psoriasis? This was in the last 10-Q:

To date, OWC has signed three research collaboration and license agreements with Sheba Academic Medical Center, Tel Hashomer, Israel ("Sheba"). Sheba is a university-affiliated hospital that serves as Israel's national medical center and the most comprehensive medical center in the Middle East. Within the framework of the agreements with Sheba, OWC will initiate three studies at the Sheba facilities to explore the effect of three formulations, all based on active ingredients in the cannabis extracts, on multiple myeloma, psoriasis and fibromyalgia (a specific formulation to each indication)...

Pursuant to the collaboration agreements, we expect to pay Sheba $330,000 for conducting the multiple myeloma trial between the 3rd quarter of 2015 and the second quarter of 2016. In addition, we expect to commence pre-clinical studies on fibromyalgia and psoriasis during the second quarter of 2016. Pursuant to the collaboration agreements, we are obliged to pay Sheba $300,000 throughout 2016 for conducting the psoriasis research, and $100,000 for the fibromyalgia research during the two years of the study. We currently have the financial resources to fund our obligations under these agreements, but anticipate that we will require additional funding during the next 12 months for our continuing and planned expanded operations.

I was searching the the Sheba - Academic Medical Hospital site and oddly didn't find any research about psoriasis and cannabis.

I did find this research: The Cannabinoids Receptors and fibrosis - the link is in Hebrew and iHub doesn't handle that very well.

Here is the link to Sheba: https://eng.sheba.co.il/ - try to find any research that the company is claiming.

IG

"Are you gonna pull those pistols or whistle Dixie?"